Stock Scorecard



Stock Summary for Legend Biotech Corp (LEGN) - $18.48 as of 10/19/2026 3:21:01 PM EST

Total Score

10 out of 30

Safety Score

31 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for LEGN

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for LEGN

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for LEGN

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for LEGN

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for LEGN (31 out of 100)

Stock Price Rating (Max of 10) 6
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 4
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 3
Analyst Strong Buy Ratings (Max of 5) 5
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 4
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) -10

Latest News for for LEGN

H.C. Wainwright keeps USD 65.00 target for Legend Biotech stock 10/17/2026 4:47:00 PM
Legend Biotech stock rises to EUR 17.60, up 3.68 percent on Nasdaq 10/15/2026 6:59:00 PM
Legend Biotech gets FDA IND clearance for dual-targeting CAR-T therapy 10/15/2026 12:41:00 PM
FDA Grants IND Approval to Legend Biotech for LB2501 Dual-Targeting CAR-T Therapy 10/15/2026 11:41:00 AM
Legend Biotech Announces U.S. FDA Clearance of IND 10/15/2026 11:41:00 AM
H.C. Wainwright reiterates Legend Biotech stock rating on strong Carvykti sales 10/15/2026 11:41:00 AM
FDA clears a study application for a therapy designed to make immune cells inside the body 10/15/2026 11:41:00 AM
Legend Biotech Receives FDA Clearance for In Vivo CAR-T Therapy Trial 10/15/2026 8:57:00 AM
Legend Biotech Corporation (LEGN) Options Chain 10/14/2026 4:10:00 PM
Barclays Maintains Legend Biotech(LEGN.US) With Buy Rating, Cuts Target Price to $68 10/14/2026 11:10:00 AM

Financial Details for LEGN

Company Overview

Ticker LEGN
Company Name Legend Biotech Corp
Country N/A
Description Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2026
Next Earnings Date 11/11/2026

Stock Price History

Last Day Price 18.48
Price 4 Years Ago 49.92
Last Day Price Updated 10/19/2026 3:21:01 PM EST
Last Day Volume 2,961,906
Average Daily Volume 2,284,988
52-Week High 37.50
52-Week Low 16.24
Last Price to 52 Week Low 13.79%

Valuation Measures

Trailing PE N/A
Industry PE 39.69
Sector PE 57.46
5-Year Average PE -83.81
Free Cash Flow Ratio 5.34
Industry Free Cash Flow Ratio 16.56
Sector Free Cash Flow Ratio 34.01
Current Ratio Most Recent Quarter 3.04
Total Cash Per Share 3.46
Book Value Per Share Most Recent Quarter 6.35
Price to Book Ratio 2.92
Industry Price to Book Ratio 13.13
Sector Price to Book Ratio 29.59
Price to Sales Ratio Twelve Trailing Months 2.93
Industry Price to Sales Ratio Twelve Trailing Months 6.07
Sector Price to Sales Ratio Twelve Trailing Months 20.93
Analyst Buy Ratings 3
Analyst Strong Buy Ratings 5

Share Statistics

Total Shares Outstanding 194,488,000
Market Capitalization 3,594,138,240
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -67.66%
Reported EPS 12 Trailing Months -0.52
Reported EPS Past Year -0.06
Reported EPS Prior Year -1.60
Net Income Twelve Trailing Months -91,604,000
Net Income Past Year -296,800,000
Net Income Prior Year -177,026,000
Quarterly Revenue Growth YOY 51.90%
5-Year Revenue Growth 68.83%
Operating Margin Twelve Trailing Months 14.90%

Balance Sheet

Total Cash Most Recent Quarter 672,921,702
Total Cash Past Year 901,900,000
Total Cash Prior Year 286,749,000
Net Cash Position Most Recent Quarter 500,991,702
Net Cash Position Past Year 600,704,000
Long Term Debt Past Year 301,196,000
Long Term Debt Prior Year 301,196,000
Total Debt Most Recent Quarter 171,930,000
Equity to Debt Ratio Past Year 0.77
Equity to Debt Ratio Most Recent Quarter 0.88
Total Stockholder Equity Past Year 1,002,100,000
Total Stockholder Equity Prior Year 1,040,546,000
Total Stockholder Equity Most Recent Quarter 1,229,639,657

Free Cash Flow

Free Cash Flow Twelve Trailing Months -255,614,012
Free Cash Flow Per Share Twelve Trailing Months -1.31
Free Cash Flow Past Year -168,043,258
Free Cash Flow Prior Year -158,138,000

Options

Put/Call Ratio 0.25
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD -0.37
MACD Signal -0.44
20-Day Bollinger Lower Band 12.72
20-Day Bollinger Middle Band 23.09
20-Day Bollinger Upper Band 33.46
Beta 0.57
RSI 51.45
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System

Modified 10/17/2026 2:51:11 AM EST